Jade Biosciences, INC. (JBIO) — 10-Q Filings

10-Q Filings (6)

• JBIO's R&D Surge Drives $95M Loss Amid Autoimmune Pipeline Push — Nov 14, 2025 Risk: high
  Jade Biosciences, Inc. (JBIO) reported a significant increase in its net loss for the nine months ended September 30, 2025, reaching $95.478 million, compared t
• Jade Biosciences Boosts Cash to $220M Post-Merger, Losses Mount — Aug 13, 2025 Risk: high
  Jade Biosciences, Inc. (JBIO) reported a significant increase in cash and cash equivalents to $220.942 million as of June 30, 2025, up from $69.386 million at D
• Aerovate Therapeutics Reports Q1 2025 Financials — Apr 25, 2025 Risk: medium
  Aerovate Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported total assets of $289.85 million and total liabilities of $
• Aerovate Therapeutics Q3 2024 Financial Update — Nov 12, 2024 Risk: medium
  Aerovate Therapeutics, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported total assets of $288.7 million and total liabilities o
• Aerovate Therapeutics Reports Q2 2024 Results — Aug 12, 2024 Risk: medium
  Aerovate Therapeutics, Inc. reported its financial results for the quarter ended June 30, 2024. The company had total assets of $287.6 million and total liabili
• Aerovate Therapeutics, Inc. Files 10-Q for Period Ending March 31, 2024 — May 13, 2024 Risk: low
  Aerovate Therapeutics, Inc. (JBIO) filed a Quarterly Report (10-Q) with the SEC on May 13, 2024. Aerovate Therapeutics, Inc. filed a 10-Q report for the period

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX